GCK inhibition as a new therapeutical approach in RASMut myeloma and possible strategy to overcome therapy resistance
Basic Information
Funding Cycle :
2024-2025
Name :
Josefine Krüger
Type of Award :
Career Development Award
Home Institution :
Charité Universitätsmedizin, Berlin, Germany
Host Institution :
Columbia University
Description
RAS mutations in multiple myeloma lead to increased germinal center kinase (GCK) expression, presenting a potential new therapeutic target. Inhibiting GCK (GCKi) has shown to reduce myeloma cell proliferation in both in vitro and in vivo models (Li et al., Blood, 2021). Additionally, unlike IMiDs, GCKi promotes the proteasomal degradation of IKZF1/3 through a pathway independent of cereblon. Our goal in this IMS-funded project is to uncover the mechanism by which GCKi regulates IKZF1 degradation and increase the efficacy of GCKI as therapeutic approach. This project aims to introduce a personalized therapeutic strategy for RAS-mutated multiple myeloma.
